Active Genetics & Molecular Biology Heart, Stroke & Blood

Hierarchical organization of haematopoietic stem- and progenitor cell populations during steady state and stress haematopoiesis

In plain English

AI plain-English summary

The bone marrow’s ability to produce healthy blood cells falters with age, and two blood disorders—clonal haematopoiesis and myelofibrosis—accelerate that decline. This matters because these disorders are common in older people and can lead to bone marrow failure or leukaemia, yet the underlying molecular mechanisms remain poorly understood. The research will map the gene networks that allow a single blood stem cell to generate all the different blood cell types, then examine how those networks break down during ageing and disease. To do this, the team will create new mouse models that precisely mimic the genetic mutations found in human patients. If successful, the project will identify specific molecules or cell types that drive disease progression. Those targets could then be tested with existing or newly developed drugs to slow or prevent the transition from pre-leukaemic states to full-blown blood cancer. The work is primarily fundamental science—understanding how regulatory networks in stem cells go awry—but it directly aims to uncover new therapeutic strategies for blood disorders that currently have limited treatment options.

View original technical description
Normal blood cell production occurs in the bone marrow and deteriorates during ageing and is impaired by blood cancer development. In this program we will study how normal blood cell production is regulated, and in particular how regulatory genes form interlinked networks that allow the many different blood cell cell types to be generated from a single stem cell. We will use this knowledge to investigate how blood cell production is perturbed in clonal hematopoiesis (CH – a preleukemic syndrome) and myelofibrosis (MF – a hyperproliferative disorder that leads to bone marrow failure). For this purpose, we will design and develop new genetic mouse models that accurately replicate the genetic events that cause CH and MF in humans. As both CH and MF occurs more frequently in the elderly, we will use these models to to identify the physiological changes that occur during ageing that contribute to perturbation of the normal regulatory networks within hematopoietic stem cells and lead to disease development. The identified molecules or cell types will then be targeted with appropriate drugs (which will be developed in necessary) for their ability to counteract disease development. In this manner we hope to develop new therapeutic strategies for these blood disorders.

View the original record at the funder ↗

Researchers

Claus Nerlov (Principal Investigator)

Related Research

Grants with similar aims, by meaning.

Delineating the cellular and molecular pathways of hematopoietic stem cell fate decisions
New therapies for myeloproliferative diseases based on multi-stage and -system analyses of the haematopoietic stem-cell niche
Haematopoietic stem cells and cancer evolution - from single cells to population dynamics
Investigating the epigenetic basis of preleukemic hematopoietic stem and progenitor cells
Haematopoiesis - Novel tools for modelling normal and perturbed haematopoiesis

Original classification

Intramural

Plain English summaries and category classifications on this site are generated by AI and may not perfectly reflect the original research.